Cardiff Oncology (CRDF) EBT Margin (2011 - 2026)
Cardiff Oncology (CRDF) posted EBT Margin of 26533.74% for Q4 2025, down 164.95% sequentially from 10014.78% in Q3 2025, and down 1100130.0% YoY from N/an in Q4 2024.
Cardiff Oncology (CRDF) EBT Margin (2011 - 2026) Analysis & Trends
Cardiff Oncology has reported EBT Margin for 15 years, with the latest figure at 26533.74% in Q4 2025.
- Quarterly EBT Margin fell 1100130.0% year-over-year to 26533.74% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 19113.8% (down 762931.0% YoY) and the FY2025 annual result came in at 17389.21%, down 365187.0% from the prior year.
- EBT Margin retreated to 26533.74% in Q4 2025 per CRDF's latest filing, from 10014.78% in the prior quarter.
- Over five years, EBT Margin peaked at 7211.35% in Q3 2023 and troughed at 31086.54% in Q4 2023.
- A 5-year average of 15174.79% and a median of 15146.58% in 2023 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2023 and 2024: EBT Margin slumped 2360763 bps in 2023, then soared 1555410 bps in 2024.
- Over 5 years, EBT Margin stood at 7330.08% in 2021, then retreated by 2 bps to 7478.91% in 2022, then slumped by 316 bps to 31086.54% in 2023, then surged by 50 bps to 15532.44% in 2024, then slumped by 71 bps to 26533.74% in 2025.
- According to Business Quant data, EBT Margin over the past three periods registered 26533.74%, 10014.78%, and 15458.62% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 13.77% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -25.06% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -2.67% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 12.09% |
| 10 | Cardiff Oncology | 60.21 Mn | 60.21 Mn | - | -8,877.88% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8,939.42% |
| Dec 31, 2025 | -26,533.74% |
| Sep 30, 2025 | -10,014.78% |
| Jun 30, 2025 | -15,458.62% |
| Mar 31, 2025 | -16,646.95% |
| Dec 31, 2024 | -15,532.44% |
| Sep 30, 2024 | -8,729.02% |
| Jun 30, 2024 | -7,920.17% |
| Mar 31, 2024 | -13,554.71% |
| Dec 31, 2023 | -31,086.54% |
| Sep 30, 2023 | -7,211.35% |
| Jun 30, 2023 | -12,890.74% |
| Mar 31, 2023 | -14,972.29% |
| Dec 31, 2022 | -7,478.91% |
| Sep 30, 2022 | -10,522.58% |
| Jun 30, 2022 | -15,320.88% |
| Mar 31, 2022 | -19,936.49% |
| Dec 31, 2021 | -7,330.08% |
| Sep 30, 2021 | -16,884.62% |
| Jun 30, 2021 | -21,071.94% |